October ended frantically as the market sold off due mostly to mutual funds locking in end of fiscal year profits. Practically every sector dropped significantly and the stem cell stocks were no exception.
- BioTime, Inc. (BTIM) = Up 26%; This pop on news that it was moving to AMEX. These stocks typically tank once they officially move. Could be a shorting opportunity
- StemCell Inc. (STEM) = Down -29%; This stock tanked due to equity financing (A.K.A dilution). The exercise price is much higher than the current share price and the dilution is less than 10%. This looks to be a bit overdone and could be a bounce candidate.
Market Cap Over 50 Million
Aastrom Biosciences (ASTM) = Cur Price: $0.32; Down -11%
BioTime, Inc. (BTIM) = Cur Price: $5.87; Up 26%
Celgene Corp (CELG) = Cur Price: $51.05; Down -10%
Cytori Therapeutics (CYTX) = Cur Price: $3.29; Down -11%
Geron Corp (GERN) = Cur Price: $6.11; Down -6%
ThermoGenesis (KOOL) = Cur Price: $0.59; Down -14%
Osiris Therapeutics (OSIR) = Cur Price: $6.35; Down -10%
StemCell Inc. (STEM) = Cur Price: $1.14; Down -29%
Market Cap Under 50 Million
Advanced Cell Technology (ACTC.OB) = Cur Price: $0.113; Down -5%
Athersys Inc. (ATHX) = Cur Price: $1.17; Up 1%
Brainstorm Cell Therapeutics (BCLI.OB) = Cur Price: $0.31; Up 12%
Bioheart Inc. (BHRT.OB) = Cur Price: $0.91; Down -12%
Cord Blood America Inc. (CBAI.OB) = Cur Price: $0.006; Unchanged
Cyro-Cell Intl (CCEL.OB) = Cur Price: $1.75; Down -18%
Neuralstem (CUR) = Cur Price: $1.27; Down -18%
International Stem Cell (ISCO.OB) = Cur Price: $0.64; Down -11%
MultiCell Technologies (MCET.OB) = Cur Price: $0.018; Down -14%
Pluristem Therapeutics (PSTI) = Cur Price: $0.98; Down -14%
Stem Cell Therapy Intl (SCII.OB) = Cur Price: $0.159; Down -9%
Stem Cell Innovations (SCLL.PK) = Cur Price: $0.0021; Down -16%
Catalyst(s):
Still, nothing has changed from the last few months.
- M&A (mergers and acquisitions) activity will be key.
Posts
